Special Issue "Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment, 2nd Edition"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: 10 November 2023 | Viewed by 652

Special Issue Editor

Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autónoma de Barcelona, 08193 Barcelona, Spain
Interests: bioactive compounds; cell signaling; drug delivery; drug discovery; enzymology; high-throughput screening; metalloproteases; molecular pharmacology; nanoparticles; neuropeptides; neurodegenerative diseases; parkinson's disease; protein-protein interaction inhibitors; protein engineering; protein structure; protease inhibitors; protein folding and aggregation; substrate specificity; X-ray crystallography
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurodegenerative disorders are typically characterized by the progressive loss of specific populations of neurons in the brain. They can be classified according to a variety of primary clinical features and are associated with characteristic molecular abnormalities. The most common neurodegenerative disorders are amyloidoses, tauopathies, α-synucleinopathies, and TDP-43 proteinopathies. Nearly all of these disorders are associated with the accumulation of protein deposits and with alterations in normal proteostasis. Despite recent advances in the field, most of the molecular mechanisms involved in disease progression are not completely understood. However, since protein aggregation is a central event in neurological disorders, a variety of novel approaches have been focused on developing novel pharmacologically active molecules targeting this process. In addition, our understanding of amyloid structures has been boosted by recent advances in the field of structural biology and cryo-EM; these advances have facilitated the recent elucidation of a large number of high-resolution amyloid structures associated with neurodegeneration. Without a doubt, such ground-breaking discoveries will facilitate the structure-based design of novel, functional, and specific protein aggregation inhibitors. Additionally, there is an increasing focus on the utilization of nanomaterials as efficient drug delivery systems targeting neurodegenerative disorders.

The focus of this Special Issue is on the development and identification of novel molecules and therapeutic approaches dedicated to treating neurodegenerative diseases. The topics include (but are not limited to) the following: the design and development of novel protein-aggregation inhibitors; drug delivery using nanotechnology; and the development and characterization of pharmacologically active compounds targeting proteostasis and neurodegeneration.

Dr. Javier Garcia-Pardo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neurodegenerative diseases
  • structure of amyloid fibrils
  • protein aggregation
  • Parkinson’s disease
  • amyloidoses
  • α-synucleinopathies
  • tauopathies
  • TDP-43 proteinopathies
  • cell signaling
  • drug discovery
  • drug delivery
  • nanotechnology
  • high-throughput screening
  • aggregation inhibitor
  • protease inhibitor
  • proteostasis

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Neurodegenerative Proteinopathies Induced by Environmental Pollutants: Heat Shock Proteins and Proteasome as Promising Therapeutic Tools
Pharmaceutics 2023, 15(8), 2048; https://doi.org/10.3390/pharmaceutics15082048 - 30 Jul 2023
Viewed by 534
Environmental pollutants’ (EPs) amount and diversity have increased in recent years due to anthropogenic activity. Several neurodegenerative diseases (NDs) are theorized to be related to EPs, as their incidence has increased in a similar way to human EPs exposure and they reproduce the [...] Read more.
Environmental pollutants’ (EPs) amount and diversity have increased in recent years due to anthropogenic activity. Several neurodegenerative diseases (NDs) are theorized to be related to EPs, as their incidence has increased in a similar way to human EPs exposure and they reproduce the main ND hallmarks. EPs induce several neurotoxic effects, including accumulation and gradual deposition of misfolded toxic proteins, producing neuronal malfunction and cell death. Cells possess different mechanisms to eliminate these toxic proteins, including heat shock proteins (HSPs) and the proteasome system. The accumulation and deleterious effects of toxic proteins are induced through HSPs and disruption of proteasome proteins’ homeostatic function by exposure to EPs. A therapeutic approach has been proposed to reduce accumulation of toxic proteins through treatment with recombinant HSPs/proteasome or the use of compounds that increase their expression or activity. Our aim is to review the current literature on NDs related to EP exposure and their relationship with the disruption of the proteasome system and HSPs, as well as to discuss the toxic effects of dysfunction of HSPs and proteasome and the contradictory effects described in the literature. Lastly, we cover the therapeutic use of developed drugs and recombinant proteasome/HSPs to eliminate toxic proteins and prevent/treat EP-induced neurodegeneration. Full article
Show Figures

Graphical abstract

Back to TopTop